<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896866</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105598</org_study_id>
    <nct_id>NCT04896866</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)</brief_title>
  <acronym>COVASP</acronym>
  <official_title>Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients: A Pragmatic Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is respiratory disease caused by the severe acute respiratory coronavirus 2&#xD;
      (SARS-CoV-2), a novel coronavirus which has spread rapidly across the world with over 149.9&#xD;
      million laboratory confirmed cases and over 3.1 million reported deaths since December 2019.&#xD;
      Approximately 4-8% of hospitalized patients with COVID-19 have co-infection with bacterial&#xD;
      pathogens however there is widespread and often broad-spectrum antibiotic use in these&#xD;
      patients.&#xD;
&#xD;
      This is a prospective, multi-center, non-inferiority pragmatic clinical trial of&#xD;
      antimicrobial stewardship prospective audit and feedback versus no antimicrobial stewardship&#xD;
      intervention on physicians attending to patients with proven SARS-CoV-2 infection confirmed&#xD;
      by nucleic acid testing in the preceding 2 weeks of hospitalization for acute COVID-19&#xD;
      pneumonia. Prospective audit and feedback is the real time review of antibacterial&#xD;
      prescriptions and immediate feedback to prescribers to optimize antimicrobial prescriptions.&#xD;
      Hospital beds will be stratified by COVID unit and critical care unit beds, and will be&#xD;
      computer randomized in a 1:1 fashion into 2 arms (antimicrobial stewardship intervention&#xD;
      versus no antimicrobial stewardship intervention) prior to study commencement at the&#xD;
      participating site. Patients hospitalized to study-eligible beds will be followed for primary&#xD;
      and secondary outcomes.&#xD;
&#xD;
      The objective of this study is to determine the effect of an antimicrobial stewardship&#xD;
      intervention (prospective audit and feedback) on clinical outcomes in patients hospitalized&#xD;
      with acute COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Hospital beds are randomized prior to enrolment to intervention versus observation. Intervention consists of antimicrobial stewardship prospective audit and feedback.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ordinal scale</measure>
    <time_frame>Day 15 of hospital admission</time_frame>
    <description>A 7 point ordinal scale of clinical outcomes:&#xD;
point - Not hospitalized, able to resume normal daily activities&#xD;
points - Not hospitalized, unable to resume normal daily activities&#xD;
points - Hospitalized, not on supplemental oxygen&#xD;
points - Hospitalized, on supplemental oxygen&#xD;
points - Hospitalized, on high flow oxygen therapy or non-invasive mechanical ventilation&#xD;
points - Hospitalized, on ECMO or invasive mechanical ventilation&#xD;
points - Death&#xD;
Higher scores means a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
    <description>Duration of hospitalization in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
    <description>Death occurring during hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality in the first 30 days after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day C. difficile associated mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Death related to C. difficile-associated diarrhea in the first 30 days after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day re-admission rate</measure>
    <time_frame>30 days from hospital discharge</time_frame>
    <description>Re-admission to hospital after initial discharge in the first 30 days after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of therapy normalized for patient-days</measure>
    <time_frame>capped at 30 days of hospitalization</time_frame>
    <description>Days of antibiotic therapy normalized for patients-day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of total antimicrobial therapy normalized for patient-days</measure>
    <time_frame>capped at 30 days of hospitalization</time_frame>
    <description>Length of antibiotics normalized for patient-days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antimicrobial stewardship audits</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
    <description>Number of audits by ASP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antimicrobial stewardship recommendations</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
    <description>Number of recommendations by ASP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial stewardship acceptance rates</measure>
    <time_frame>through study completion, an average of 5 days</time_frame>
    <description>Acceptance rate of ASP recommendations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multi-drug resistant bacteria infection rates</measure>
    <time_frame>30 days</time_frame>
    <description>Development of multi-drug resistant bacterial infection in the first 30 days after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridioides difficile infection rate</measure>
    <time_frame>30 days</time_frame>
    <description>C. difficile-associated diarrhea in the first 30 days after diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with neutropenia</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of neutropenia in the first 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>30 days</time_frame>
    <description>diagnosed and staged as according to KDIGO</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Covid19</condition>
  <condition>COVID-19 Pneumonia</condition>
  <condition>COVID-19 Lower Respiratory Infection</condition>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>SARS-CoV2 Infection</condition>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Antimicrobial stewardship</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antimicrobial stewardship prospective audit and feedback on physicians attending to patients admitted with community-acquired COVID-19 pneumonia to beds randomized to antimicrobial stewardship intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antimicrobial stewardship</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No antimicrobial stewardship prospective audit and feedback.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Antimicrobial stewardship prospective audit and feedback</intervention_name>
    <description>Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.</description>
    <arm_group_label>Antimicrobial stewardship</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years at the time of hospital admission.&#xD;
&#xD;
          -  Confirmed SARS-CoV-2 infection by nucleic acid testing in the preceding 14 days of&#xD;
             hospital admission.&#xD;
&#xD;
          -  Admitted from the community (including continuing care facilities).&#xD;
&#xD;
          -  Admitted to a hospital bed designated in the study.&#xD;
&#xD;
          -  SpO2 ≤94% requiring supplemental oxygen or chest imaging findings compatible with&#xD;
             COVID-19 pneumonia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is enrolled in another clinical trial that involves antibacterial therapy.&#xD;
&#xD;
          -  The patient's goals of care is anticipated to be designated &quot;total compassionate care&quot;&#xD;
             or palliative care within 48 hours of admission.&#xD;
&#xD;
          -  The patient's progression to death is anticipated to be imminent and inevitable within&#xD;
             48 hours of admission.&#xD;
&#xD;
          -  The patient was attended by any member of the research team within 30 days of&#xD;
             enrollment.&#xD;
&#xD;
          -  The patient is transferred from another acute care center.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Justin Chen, MD</last_name>
    <phone>+17804928782</phone>
    <email>jzchen@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Misericordia Community Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5R 4H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Hoang, MD</last_name>
      <phone>+17807357236</phone>
      <email>hlhoang@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Holly Hoang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Chen, MD</last_name>
      <phone>+17804928782</phone>
      <email>jzchen@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Justin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Cervera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Doucette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dima Kabbani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Community Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Hoang, MD</last_name>
      <phone>+17807357236</phone>
      <email>hlhoang@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Holly Hoang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, Heywood A. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis. 2018 Dec 7;18(1):637. doi: 10.1186/s12879-018-3548-0. Review.</citation>
    <PMID>30526505</PMID>
  </reference>
  <reference>
    <citation>Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J 4th, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ. Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013-14. J Clin Virol. 2016 Jul;80:12-9. doi: 10.1016/j.jcv.2016.04.008. Epub 2016 Apr 14.</citation>
    <PMID>27130980</PMID>
  </reference>
  <reference>
    <citation>Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530. Review.</citation>
    <PMID>32358954</PMID>
  </reference>
  <reference>
    <citation>Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016. Epub 2020 Jul 22.</citation>
    <PMID>32711058</PMID>
  </reference>
  <reference>
    <citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.</citation>
    <PMID>32007143</PMID>
  </reference>
  <reference>
    <citation>Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388. doi: 10.1164/rccm.202002-0445OC.</citation>
    <PMID>32275452</PMID>
  </reference>
  <reference>
    <citation>Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X, Lv J, Luo Y, Shen L, Yang H, Huang G, Yang R. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020 Jul;92(7):797-806. doi: 10.1002/jmv.25783. Epub 2020 Apr 1.</citation>
    <PMID>32198776</PMID>
  </reference>
  <reference>
    <citation>Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):769-777. doi: 10.1093/cid/ciaa272.</citation>
    <PMID>32176772</PMID>
  </reference>
  <reference>
    <citation>Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, Yang AY, Yu BP, Huang ZP. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020 Apr 29;20(1):311. doi: 10.1186/s12879-020-05010-w.</citation>
    <PMID>32345226</PMID>
  </reference>
  <reference>
    <citation>Cao J, Hu X, Cheng W, Yu L, Tu WJ, Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Med. 2020 May;46(5):851-853. doi: 10.1007/s00134-020-05987-7. Epub 2020 Mar 2. Erratum in: Intensive Care Med. 2020 Apr 14;:.</citation>
    <PMID>32123993</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Barrasa H, Rello J, Tejada S, Martín A, Balziskueta G, Vinuesa C, Fernández-Miret B, Villagra A, Vallejo A, San Sebastián A, Cabañes S, Iribarren S, Fonseca F, Maynar J; Alava COVID-19 Study Investigators. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. Anaesth Crit Care Pain Med. 2020 Oct;39(5):553-561. doi: 10.1016/j.accpm.2020.04.001. Epub 2020 Apr 9.</citation>
    <PMID>32278670</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P, Li T, Cao F, Chang C, Hu Q, Jin Y, Xu G. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379. doi: 10.1164/rccm.202003-0543OC.</citation>
    <PMID>32242738</PMID>
  </reference>
  <reference>
    <citation>Polgreen PM, Chen YY, Cavanaugh JE, Ward M, Coffman S, Hornick DB, Diekema DJ, Herwaldt LA. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007 Feb;28(2):212-4. Epub 2007 Jan 25.</citation>
    <PMID>17265406</PMID>
  </reference>
  <reference>
    <citation>Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, Laksman Z, Healey JS, Krahn AD. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020 Jun;36(6):948-951. doi: 10.1016/j.cjca.2020.04.003. Epub 2020 Apr 8.</citation>
    <PMID>32299753</PMID>
  </reference>
  <reference>
    <citation>Clancy CJ, Nguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin Infect Dis. 2020 Dec 17;71(10):2736-2743. doi: 10.1093/cid/ciaa524.</citation>
    <PMID>32361747</PMID>
  </reference>
  <reference>
    <citation>Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck. Infect Control Hosp Epidemiol. 2020 Jun;41(6):744-745. doi: 10.1017/ice.2020.69.</citation>
    <PMID>32167442</PMID>
  </reference>
  <reference>
    <citation>Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19. Erratum in: Lancet Infect Dis. 2020 Sep;20(9):e215.</citation>
    <PMID>32087114</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antimicrobial stewardship</keyword>
  <keyword>antibiotic stewardship</keyword>
  <keyword>prospective audit and feedback</keyword>
  <keyword>quality improvement</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol will be published in an open journal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

